BON

Business Context and Reporting Period

Bon Natural Life Ltd (BON) is a bio-ingredient solutions provider engaged in the research, development, and manufacturing of functional active ingredients extracted from natural herb plants for the functional food, personal care, cosmetic, and pharmaceutical industries. This Form 6-K filing, dated August 17, 2021, presents unaudited financial results and management discussion for the six-month period ended March 31, 2021.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 63.6% ($4.55 million) driven by a 90.1% volume increase in fragrance compounds and a 306.3% volume increase in health supplemental powder drinks. This growth was partially offset by a 51.4% volume decrease in bioactive food ingredients (specifically Stachyose) as pandemic-related demand subsided.
• Margin Compression: Gross margin decreased by 6.9 percentage points to 28.8%. This was caused by a shift in product mix toward lower-margin items, reduced selling prices for bioactive ingredients due to improved extraction efficiency, and increased raw material costs.
• Expense Reduction: Total operating expenses decreased by 16.1% to $839,299. Selling expenses dropped due to reduced travel and trade shows, while G&A expenses fell primarily due to lower consulting fees compared to the IPO preparation period in 2020.
• Profitability: Net income increased by 43.9% to $2.3 million, despite a higher provision for income taxes ($465,077 vs. $249,766) resulting from increased taxable income.

Guidance, Outlook, and Risks

• Recent Developments: The Company completed its IPO on June 28, 2021, raising net proceeds of approximately $11.3 million. It also acquired land for a new manufacturing facility (Yumen Plant) with a budget of $3.0 million, with construction expected to complete in June 2022.
• Liquidity and Capital Resources: As of March 31, 2021, the Company held $1.04 million in cash and had $8.9 million in accounts receivable (97.4% subsequently collected). Management expects liquidity to be sufficient for the next 12 months, supported by IPO proceeds, $7.8 million in available credit lines, and a pledge of financial support from the controlling shareholder.
• Tax Liabilities: The Company reported approximately $5.7 million in unpaid tax liabilities (VAT and income tax) as of March 31, 2021. Management expects to settle these with local authorities by December 31, 2021, without penalty.
• Risks: The Company faces ongoing risks from the COVID-19 pandemic, including potential supply chain disruptions and reduced customer payments. Additionally, the Company relies on government subsidies and preferential tax rates for High and New Technology Enterprises (HNTEs), which require re-application every three years.

Investor Verification Checklist

• Tax Liability Settlement: Verify the status of the $5.7 million unpaid tax liability and confirm the timeline for settlement with local Chinese tax authorities.
• Accounts Receivable Collection: Confirm the collection of the remaining 2.6% of accounts receivable outstanding as of March 31, 2021.
• Product Mix Sustainability: Assess the long-term demand for fragrance compounds and health supplements versus the volatility of bioactive food ingredients (Stachyose) which saw a sharp decline post-pandemic peak.
• Capital Expenditure Funding: Monitor the funding of the $1.6 million remaining commitment for the Tongchuan manufacturing project and the $3.0 million Yumen Plant construction.
• HNTE Status: Verify the Company's continued eligibility for the 15% preferential tax rate as a High and New Technology Enterprise.